SG
TRDA icon

StepStone Group’s Entrada Therapeutics TRDA Stock Holding History

StepStone Group’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.6M Hold
761,277
– – 0.26% 9
2026
Q1 		$9.61M Hold
761,277
– – 4.63% 7
2025
Q4 		$7.83M Hold
761,277
– – 4.19% 5
2025
Q3 		$4.42M Hold
761,277
– – 2.08% 8
2025
Q2 		$5.12M Hold
761,277
– – 10.14% 4
2025
Q1 		$6.88M Hold
761,277
– – 7.07% 4
2024
Q4 		$13.2M Hold
761,277
– – 11.51% 3
2024
Q3 		$12.2M Hold
761,277
– – 4.44% 7
2024
Q2 		$10.8M Hold
761,277
– – 2.2% 8
2024
Q1 		$10.8M Hold
761,277
– – 2.29% 8
2023
Q4 		$11.5M Hold
761,277
– – 2.07% 8
2023
Q3 		$12M Hold
761,277
– – 2.68% 7
2023
Q2 		$11.5M Hold
761,277
– – 2.13% 7
2023
Q1 		$11M Hold
761,277
– – 2.05% 7
2022
Q4 		$10.3M Hold
761,277
– – 1.34% 12
2022
Q3 		$12M Buy
761,277
+126,318
+20% +$1.6M 1.71% 10
2022
Q2 		$7.73M Sell
634,959
-126,318
-17% -$958K 0.83% 15
2022
Q1 		$7.15M Hold
761,277
– – 0.53% 14
2021
Q4 		$13M Buy
+761,277
New +$18.5M 0.74% 13

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MC
Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

StepStone Group's TRDA Position: Q2 2026 in Review

StepStone Group held its Entrada Therapeutics (TRDA) position steady in Q2 2026 at 761,277 shares worth $5.6M. The position accounts for 0.26% of the portfolio, ranked #9.

StepStone Group first reported a position in TRDA in Q4 2021 and has held it in 19 quarters since. The position peaked at $13.2M in Q4 2024. 129 funds tracked by Wall St. Rank hold TRDA as of Q2 2026.

  • StepStone Group held 761,277 shares of Entrada Therapeutics worth $5.6M as of Q2 2026.
  • StepStone Group left its Entrada Therapeutics share count unchanged in Q2 2026.
  • Entrada Therapeutics made up 0.26% of StepStone Group's portfolio in Q2 2026, its #9 holding.
  • StepStone Group first reported a position in Entrada Therapeutics in Q4 2021 and has held it in 19 quarters since.
  • StepStone Group's Entrada Therapeutics position peaked at $13.2M in Q4 2024.
  • 129 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q2 2026.

Based on StepStone Group's 13F filing for Q2 2026, filed 13 Aug 2026.